Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...

The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...

Bavarian Nordic has won US Food and Drug Administration (FDA) approval for its chikungunya vaccine Vimkunya, becoming the second company in the US to market a vaccine for the tropical disease.

With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...